ESPE2015 Poster Category 3 Fat (88 abstracts)
aDepartment of Medical Sciences, Pediatrics, University of Foggia, Foggia, Italy; bAssistance Publique-Hôpitaux de Paris, Service de Médecine des Adolescents, Hôpitaux Universitaires Paris Sud, CHU Bicêtre, Le Kremlin-Bicêtre, France; cDepartment of Diagnostic Imaging, Radiology, University of Foggia, Foggia, Italy
Background: Despite the metabolic syndrome in pediatrics is a well recognized entity, there is no unanimous consensus on exact value of MS to predict long-term cardiovascular risk. Hepatic Steatosis (HS) is another emerging condition associated to pediatric obesity.
Objective and hypotheses: To evaluate the prevalence of MS in a large pediatric obese population, assess the relationship between MS and HS, and evaluating the possible role of HS in defining the syndrome and modulating the cardiovascular impact.
Method: We studied 803 overweight and obese children (395 girls and 408 boys, mean age 9.43±2.5 years, BMI z-score 2.23±0.53 with complete clinical and biological assessment. MS was defined using criteria of American Heart Association. The diagnosis and severity of HS was based on ultrasound scan. All patients underwent an ultrasonography to measure carotidal intima-media thickness (cIMT), a validated marker of subclinical atherosclerosis.
Results: The overall prevalence of MS was 13.07% and was significantly higher in patients with MS: 40.9% vs 18.5% (P<0.0001). Spearmans correlation between HS grade and the number of MS criteria was significant (ρ=0.285 P<0.0001). No statistical difference was recorded about cIMT and cIMT z-score between patients with or without MS, until inclusion of HS as additional criterion for the diagnosis of MS. In this case, there was significant difference in cIMT and cIMT z-score between the two groups. In multiple stepwise linear regression analysis, cIMT z-score was better predicted by using HS grade and (ρ=0.279, adjusted R2: 2.6%, P<0.0001), than using only MS cluster.
Conclusion: HS should be used as additional criterion in detecting pediatric MS phenotype at higher risk for long-term cardiovascular morbidity.